 |
|
|
| |
Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
|
| |
| |
EASL 2024 June 5-8 Milan Italy
|
| |
|
|
|
|
|
